| Description | PGS-IN-1 (KME-4) is a potent inhibitor of prostaglandin synthetase (PGS, IC50: 0.28 μM) and 5-lipoxygenase (IC50: 1.05 μM). |
| In vitro | PGS-IN-1 is the trans isomer of the synthesized α-benzulidene-γ-butyrolactone. PGS-IN-1 exhibits potent anti-inflammatory and PGS inhibitory activity with IC50 of 0.28 μM[1]. PGS-IN-1 also shows potent inhibitory activity against 5-lipoxygenase with IC50 of 1.05 μM[1]. |
| Target activity | PGS:0.28 μM, 5-LOX:1.05 μM |
| Synonyms | KME-4 |
| molecular weight | 302.41 |
| Molecular formula | C19H26O3 |
| CAS | 102271-49-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/ml (181.87 mM) |
| References | 1. Katsumi I, et al. Studies on styrene derivatives. I. Synthesis and antiinflammatory activities of alpha-benzylidene-gamma-butyrolactone derivatives. Chem Pharm Bull (Tokyo). 1986 Jan;34(1):121-9. |